Evidence map›Paper›PMID 35372900›Full record

Trial reportKidney3602020

Combination Hydralazine and Isosorbide Dinitrate in Dialysis-Dependent ESRD (HIDE): A Randomized, Placebo-Controlled, Pilot Trial.

David M Charytan, Jesse Y Hsu, Finnian R Mc Causland, Sushrut S Waikar, T Alp Ikizler, Dominic S Raj, J Richard Landis, Rajnish Mehrotra, Mark Williams, Marcelo DiCarli and 5 more

Open access · diamondAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Kidney360, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed, 1 pooled it
0.3field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 1 synthesis or guideline pooled it, 5 citations in OpenAlex.

  1. Guideline
  2. Review
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 11 institutions in 1 country.

David M CharytanDivision of Nephrology, Department of Medicine, New York University Grossman School of Medicine, New York, New York.
Jesse Y HsuDepartment of Biostatistics, Epidemiology and Informatics, and Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Finnian R Mc CauslandRenal Division, Department of Medicine, Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts.
Sushrut S WaikarRenal Section, Department of Medicine, Boston University Medical Center, Boston, Massachusetts.
T Alp IkizlerDivision of Nephrology and Hypertension, Department of Medicine, and Vanderbilt Center for Kidney Disease, Vanderbilt University Medical Center, Nashville, Tennessee.
Dominic S RajDivision of Renal Diseases and Hypertension, George Washington University School of Medicine, Washington, DC.
J Richard LandisDepartment of Biostatistics, Epidemiology and Informatics, and Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Rajnish MehrotraDivision of Nephrology, Department of Medicine, Kidney Research Institute, University of Washington, Seattle, Washington.
Mark WilliamsRenal Division, Beth Israel Deaconess Medical Center, Boston, Massachusetts.
Marcelo DiCarliDepartments of Radiology and Medicine, Brigham and Women's Hospital, Boston, Massachusetts.
Hicham SkaliCardiovascular Division, Department of Medicine, Harvard Medical School and Brigham and Women's Hospital, Boston, Massachusetts.
Paul L KimmelNational Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, Maryland.
Alan S KligerDepartment of Medicine, Yale School of Medicine, New Haven, Connecticut.
Laura M DemberRenal, Electrolyte and Hypertension Division, and Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.
Hemodialysis Novel Therapies Consortium
University of Pennsylvania · USHarvard University · USBeth Israel Deaconess Medical Center · USBoston University · USBrigham and Women's Hospital · USGeorge Washington University · USNational Institute of Diabetes and Digestive and Kidney Diseases · USNew York University · USUniversity of Washington · USVanderbilt University Medical Center · USYale University · US

Funding

Harvard Clinical and Translational Science CenterUL1TR001102 · NCATS · HARVARD MEDICAL SCHOOL · PI NADLER, LEE MARSHALL · 2013 to 2017
$106.2M
Data Coordinating Center for Hemodialysis Pilot Studies ConsortiumU01DK099919 · NIDDK · UNIVERSITY OF PENNSYLVANIA · PI DEMBER, LAURA M, LANDIS, J RICHARD · 2013 to 2018
$5.2M
Anti-Inflammatory Interventions in Maintenance Hemodialysis PatientsU01DK099923 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI HIMMELFARB, JONATHAN, IKIZLER, TALAT ALP · 2013 to 2018
$2.6M
Aldosterone, nitric oxide, myocardial fibrosis, and capillary loss in ESRDU01DK096189 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI MCCAUSLAND, FINNIAN R · 2013 to 2017
$2.4M
Gut Microbiota and Atherosclerosis in ESRDU01DK099914 · NIDDK · GEORGE WASHINGTON UNIVERSITY · PI RAJ, DOMINIC S · 2013 to 2017
$1.9M
Cardiac Complications of Hemodynamic Instability during HemodialysisK23DK102511 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI MCCAUSLAND, FINNIAN R · 2015 to 2019
$964k
NO, myocardial fibrosis, and microvascular rarefaction in ESRD: Pilot StudiesR21DK100772 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI CHARYTAN, DAVID M · 2014 to 2015
$486k
Patient Symptoms on Hemodialysis-Timing, Variability and CausesR03DK122240 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI MCCAUSLAND, FINNIAN R · 2019 to 2020
$179k
NCATS NIH HHS UL1 TR001102NIDDK NIH HHS K23 DK102511NIDDK NIH HHS R03 DK122240NIDDK NIH HHS R21 DK100772NIDDK NIH HHS U01 DK096189NIDDK NIH HHS U01 DK099914NIDDK NIH HHS U01 DK099919NIDDK NIH HHS U01 DK099923
6 · The paper itself

Abstract

Background: Combination therapy with isosorbide dinitrate (ISD) and hydralazine (HY) reduces heart failure mortality. The safety and tolerability in individuals requiring maintenance hemodialysis (HD) is unknown. Methods: Single-center, randomized, placebo-controlled, double-blind pilot trial to explore safety and tolerability of ISD/HY in maintenance HD. Participants were randomized to placebo or combination ISD/HY. Dose was escalated over 3 weeks from ISD 10 mg/HY 10 mg to ISD 40 mg/HY 75 mg three times per day with the maximum tolerated dose maintained for the subsequent 21 weeks. Primary endpoints included adverse events, adverse events precluding further treatment with study medication, serious hypotension ( Results: A total of 17 individuals were randomized to ISD/HY ( Conclusions: ISD/HY appears to be well tolerated in patients being treated with maintenance HD, but headache and gastrointestinal side effects occur more frequently with ISD/HY compared with placebo.

Indexed as

Isosorbide DinitrateKidney Failure, ChronicHumansHydralazinePilot ProjectsRenal DialysisTomography, X-Ray ComputedHydralazineIsosorbide Dinitratechronic kidney diseasechronic kidney failurehemodialysishydralazineisosorbide dinitratepilot projectsrandomized controlled trialrenal dialysis

Identifiers

PMID35372900
PMCPMC8815530
OpenAlexW3093442910

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.